1. Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma
Yan GU ; Yahui YUAN ; Qinglin SHI ; Xiaoyan QU ; Ji XU ; Rui GUO ; Jiadai XU ; Jianyong LI ; Lijuan CHEN
Chinese Journal of Hematology 2017;38(4):279-284
Objective:
To observe the efficacy and safety of CTD (cyclophosphamide, thalidomide, dexamethasone) and PCD (bortezomib, cyclophosphamide, dexamethasone) regimens in treatment of patients with newly diagnosed multiple myeloma (NDMM) .
Methods:
A retrospective analysis was carried out on 88 cases of NDMM patients admitted to our hospital from July 2013 to January 2016, including 49 cases in CTD group and 39 cases in PCD group. The outcomes of two different regimens were analyzed, including response, prognosis, and adverse events.
Results:
The total overall remission rates (ORR, better than PR) of CTD and PCD were 65.3% (32/49) and 84.6% (33/39) , while very good partial response (VGPR) were 30.6% (15/49) and 53.8% (21/39) , and differences were statistically significant (